Acquisition of an Agilent-BioTek Multimode Plate Reader
Inactive on SAM.gov — responses were due 6 Sep 2026 · No Set aside used · National Institutes of Health (NIH), HHS · Bethesda, MD · NAICS 325414 · Solicitation 75N98026Q01117AGILENTTECHNOLOGIESPCANIDDK06663
Following NAICS 325414? Get new solicitations in it by email as they post — no account needed.
SAM.gov marked this notice inactive — responses were due 06 September 2026.
No award notice on SAM.gov yet. Not every award is posted there, so this does not mean it went unawarded.
Email me when the award is announced. One email, when SAM.gov posts the award notice. Not every award is posted there; if none appears within six months we'll tell you and stop. No account needed.
This one has closed. We'll email you when new NAICS 325414 (Biological Product (Except Diagnostic) Manufacturing) solicitations post — the first email lists what is open right now, then at most once a week, only when something new posts. No account needed; unsubscribe in a click.
Description
The purpose of this requirement is to acquire a microplate reader for the National Institute of Diabetes and Digestive and Kidney Diseases to support biochemical and biophysical analyses. The instrument measures absorbance, fluorescence, and luminescence from samples in a multi-well plate format, enabling detection and quantification of biological molecules and cellular processes. The system supports high-throughput, automated workflows and includes temperature control, liquid handling capability, and adjustable optical settings for live-cell assays. The requested unit will replace an existing instrument that has become outdated and unreliable. The replacement system is compatible with existing laboratory software, allowing continuity of current experimental protocols and data analysis methods. Justification: Microplate-based measurements are critical to research conducted by the National Institute of Diabetes and Digestive and Kidney Diseases, including studies of metabolism, cellular function, and disease mechanisms such as obesity and diabetes. The current instrument lacks sufficient sensitivity for luminescence-based assays and does not meet the speed requirements for time-sensitive measurements, resulting in reduced data quality and efficiency. The replacement unit provides improved sensitivity and faster read speeds, directly addressing these limitations. The existing instrument is no longer supported under a service contract, increasing the risk of failure and potential disruption to ongoing federally funded research. Failure to acquire this instrument may result in suspension of critical experiments, delays in research progress, and increased costs associated with rework and equipment downtime.
FedSift reads the full solicitation package — every attachment — and pre-extracts the compliance matrix, evaluation factors, key risks, win themes and deal-breakers, each with a verbatim quote and the exact PDF page it came from. It scores the opportunity against your company profile, tells you whether to bid as prime or sub, and ranks teaming partners who could close your gaps.
Source: this notice on SAM.gov. FedSift republishes public federal procurement data and is not affiliated with the U.S. Government. Always confirm dates and requirements against SAM.gov before responding.
